Swedish Orphan Biovitrum AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
For the six months, sales was SEK 8,801 million compared to SEK 6,872 million a year ago. Net income was SEK 801 million compared to SEK 964 million a year ago. Basic earnings per share from continuing operations was SEK 2.71 compared to SEK 3.27 a year ago. Diluted earnings per share from continuing operations was SEK 2.69 compared to SEK 3.26 a year ago.